|
|
 |
|
Viewing report
|
|
|
|
Biosimilars, Biogenerics and Follow-On Biologics
VOI Consulting, Inc., April 2009, Pages: 50+
Biosimilars, biogenerics or follow-on biologics – by any name, second generation versions of blockbuster biologic products are coming to America and they are going to have a profound impact on all aspects of the pharmaceutical industry. Now, from the publisher of PharmaHandbook and GenericHandbook, is offering Biosimilars: Problems, Prospects and Projections, a single-source analysis of this fast-moving topic, for immediate download.
Written in April 2009, this report provides current information on the economic, manufacturing, regulatory, legislative, competitive and marketing issues that make biosimilars such a lucrative but challenging opportunity. Although focused on the U.S., the report also examines developments in Japan, Canada, Australia, India and China. Experiences in the European Union, which has the most advanced biosimilar sector, are given special attention. An appendix provides summaries and links to a dozen recent economic, scientific and commercial studies on the subject.
Biosimilars are already changing business models and bringing in a whole new set of competitors. Buy Biosimilars: Problems, Prospects and Projections today and get out in front of what is certain to be one of the industry-transforming issues of the coming decade.
Customers who bought this item also bought
A Guide to Biosimilars, Biogenerics and Follow-On Biologics
Negotiating the Emerging Biosimilars Landscape: Key Developments in the Regulatory Environment
Meeting the Challenges of Manufacturing Biosimilars
Biosimilars: A Viable Market - But When?
Biosimilars (2009 - 2014)
Biosimilars Series: Regulatory and development issues hurdles exist but are surmountable
Biosimilars: Beyond the first product wave
Biosimilars and Biobetters: Positioning for a New Market
Biosimilars - Evolution or Revolution?
Biosimilars Series: Forecast Analysis
The Future of Biosimilars: Key Opportunities & Emerging Therapies
Biosimilars Series: Stakeholder Analysis
|
|
|
|
